Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impaired Antibody-Dependent Cellular Cytotoxicity in a Spanish Cohort of Patients With COVID-19 Admitted to the ICU.
Vigón L, García-Pérez J, Rodríguez-Mora S, Torres M, Mateos E, Castillo de la Osa M, Cervero M, Malo De Molina R, Navarro C, Murciano-Antón MA, García-Gutiérrez V, Planelles V, Alcamí J, Pérez-Olmeda M, Coiras M, López-Huertas MR. Vigón L, et al. Front Immunol. 2021 Sep 20;12:742631. doi: 10.3389/fimmu.2021.742631. eCollection 2021. Front Immunol. 2021. PMID: 34616404 Free PMC article.
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
Ayala R, Fernández RA, García-Gutiérrez V, Alvarez-Larrán A, Osorio S, Sánchez-Pina JM, Carreño-Tarragona G, Álvarez N, Gómez-Casares MT, Duran A, Gorrochategi J, Hernández-Boluda JC, Martínez-López J. Ayala R, et al. EJHaem. 2023 Apr 16;4(2):401-409. doi: 10.1002/jha2.685. eCollection 2023 May. EJHaem. 2023. PMID: 37206258 Free PMC article.
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis.
Hernández-Sánchez A, Villaverde-Ramiro Á, Arellano-Rodrigo E, Garrote M, Martín I, Mosquera-Orgueira A, Gómez-Casares MT, Ferrer-Marín F, Such E, Velez P, Ayala R, Angona A, de Las Heras N, Magro E, Mata-Vázquez MI, Fox ML, de Villambrosía SG, Ramírez MJ, García A, García-Gutiérrez V, Cáceres A, Durán MA, Senín A, Raya JM, González JA, Cuevas B, Xicoy B, Pérez-Encinas M, Bellosillo B, Álvarez-Larrán A, Hernández-Rivas JM, Hernández-Boluda JC; Spanish MPN Group (GEMFIN). Hernández-Sánchez A, et al. Among authors: garcia gutierrez v. Am J Hematol. 2024 Apr;99(4):755-758. doi: 10.1002/ajh.27203. Epub 2024 Jan 30. Am J Hematol. 2024. PMID: 38291566
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson SM, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Shah NP, et al. Br J Haematol. 2023 Sep;202(5):942-952. doi: 10.1111/bjh.18883. Epub 2023 May 29. Br J Haematol. 2023. PMID: 37246588
Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.
Pérez-Lamas L, Luna A, Boque C, Xicoy B, Giraldo P, Pérez López R, Ruiz Nuño C, De Las Heras N, Mora Casterá E, López Marín J, Segura Díaz A, Gómez V, Vélez Tenza P, Sierra Pacho M, Vera Goñi JA, Moreno Vega M, Alvarez-Larrán A, Cortés M, Pérez Encinas M, Carrascosa Mastell P, Angona A, Rosell A, Lakhwani S, Colorado M, Ramila E, Cervero C, Cuevas B, Villalón Blanco L, de Paz R, Paz Coll A, Fernández MJ, Felipe Casado L, Alonso-Domínguez JM, Anguita Arance MM, Salamanca Cuenca A, Jiménez-Velasco A, Prendes SO, Santaliestra M, Lis Chulvi MJ, Hernández-Boluda JC, García-Gutiérrez V. Pérez-Lamas L, et al. Cancers (Basel). 2023 Feb 7;15(4):1045. doi: 10.3390/cancers15041045. Cancers (Basel). 2023. PMID: 36831388 Free PMC article.
Evaluation of resistance to HIV-1 infection ex vivo of PBMCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors.
Bermejo M, Ambrosioni J, Bautista G, Climent N, Mateos E, Rovira C, Rodríguez-Mora S, López-Huertas MR, García-Gutiérrez V, Steegmann JL, Duarte R, Cervantes F, Plana M, Miró JM, Alcamí J, Coiras M. Bermejo M, et al. Biochem Pharmacol. 2018 Oct;156:248-264. doi: 10.1016/j.bcp.2018.08.031. Epub 2018 Aug 22. Biochem Pharmacol. 2018. PMID: 30142322
Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.
Vigón L, Rodríguez-Mora S, Luna A, Sandonís V, Mateos E, Bautista G, Steegmann JL, Climent N, Plana M, Pérez-Romero P, de Ory F, Alcamí J, García-Gutierrez V, Planelles V, López-Huertas MR, Coiras M. Vigón L, et al. Biochem Pharmacol. 2020 Dec;182:114203. doi: 10.1016/j.bcp.2020.114203. Epub 2020 Aug 20. Biochem Pharmacol. 2020. PMID: 32828803 Free PMC article.
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.
Vigón L, Luna A, Galán M, Rodríguez-Mora S, Fuertes D, Mateos E, Piris-Villaespesa M, Bautista G, San José E, Rivera-Torres J, Steegmann JL, de Ory F, Pérez-Olmeda M, Alcamí J, Planelles V, López-Huertas MR, García-Gutiérrez V, Coiras M. Vigón L, et al. J Clin Med. 2020 Dec 25;10(1):42. doi: 10.3390/jcm10010042. J Clin Med. 2020. PMID: 33375572 Free PMC article.
Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity.
Vigón L, Fuertes D, García-Pérez J, Torres M, Rodríguez-Mora S, Mateos E, Corona M, Saez-Marín AJ, Malo R, Navarro C, Murciano-Antón MA, Cervero M, Alcamí J, García-Gutiérrez V, Planelles V, López-Huertas MR, Coiras M. Vigón L, et al. Front Immunol. 2021 May 26;12:665329. doi: 10.3389/fimmu.2021.665329. eCollection 2021. Front Immunol. 2021. PMID: 34122423 Free PMC article.
113 results